10-May-2024
TipRanks (Fri, 10-May 8:40 AM ET)
Buy Rating on Charles River Labs Amidst Solid Q1 Performance and Positive Market Outlook
TipRanks (Fri, 10-May 5:08 AM ET)
Charles River Laboratories International files automatic mixed shelf
Seeking Alpha News (Thu, 9-May 4:46 PM ET)
Charles River Laboratories Non-GAAP EPS of $2.27 beats by $0.21, revenue of $1.01B beats by $16.54M
Seeking Alpha News (Thu, 9-May 7:14 AM ET)
Charles River Laboratories Announces First-Quarter 2024 Results
Business Wire (Thu, 9-May 7:00 AM ET)
Notable earnings before Thursday's open
Seeking Alpha News (Wed, 8-May 12:34 PM ET)
Charles River Laboratories Q1 2024 Earnings Preview
Seeking Alpha News (Wed, 8-May 11:40 AM ET)
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
Business Wire (Thu, 2-May 8:00 AM ET)
Globe Newswire (Tue, 23-Apr 5:34 PM ET)
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Business Wire (Mon, 22-Apr 8:00 AM ET)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Charles River Laboratories International trades on the NYSE stock market under the symbol CRL.
As of May 10, 2024, CRL stock price declined to $228.12 with 766,268 million shares trading.
CRL has a beta of 1.54, meaning it tends to be more sensitive to market movements. CRL has a correlation of 0.36 to the broad based SPY ETF.
CRL has a market cap of $11.59 billion. This is considered a Large Cap stock.
Last quarter Charles River Laboratories International reported $1 billion in Revenue and $2.27 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.20.
In the last 3 years, CRL stock traded as high as $460.21 and as low as $161.65.
The top ETF exchange traded funds that CRL belongs to (by Net Assets): VTI, VB, VOO, VBK, SPY.
CRL has underperformed the market in the last year with a price return of +22.4% while the SPY ETF gained +27.8%. CRL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.7% and -0.4%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
CRL support price is $225.39 and resistance is $234.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRL stock will trade within this expected range on the day.